<div id="readability-page-1"><p>In a report released on December 10, Ingrid Zhang from UBS maintained a Hold rating on Giant Biogene Holding Co. Ltd., with a price target of <span id="expert-recommendation-target">HK$39.50</span>. The company’s shares closed yesterday at HK$36.20.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Zhang is a 2-star analyst with an average return of <span>13.1%</span> and a 33.33% success rate.</p> <p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for Giant Biogene Holding Co. Ltd. with a HK$56.45 average price target, representing a 55.94% upside. In a report released on December 3, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a HK$43.00 price target.</p></div>

02367

<p>UBS analyst Ingrid Zhang maintained a Hold rating for Giant Biogene Holding Co. Ltd. with a price target of HK$39.50. The stock closed at HK$36.20. Despite a general Strong Buy consensus with a HK$56.45 target, another report also reiterated a Hold rating with a HK$43.00 target.</p>

UBS Sticks to Its Hold Rating for Giant Biogene Holding Co. Ltd. (2367)